Vaishali Sanchorawala, MBBS
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College



Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.

Director
Boston University School of Medicine
Amyloidosis Center


Active Staff Hospital Privileges
Boston Medical Center
Medicine



2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract


A PHASE I DOSE-ESCALATION STUDY OF CARFLIZOMIB IN PATIENTS WITH PREVIOUSLY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium

A PHASE 3 RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIAN'S CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTO
09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.

PHASE II STUDY OF THE COMBINATION BENDAMUSTINE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AL AMYLOIDOSIS
09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.

A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY OF INTRAVENOUS ADMINISTRATION OF SINGLE AGENT NEOD001 IN SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited

MOLECULAR IMAGING OF PRIMARY AMYLOID CARDIOMYOPATHY
04/01/2017 - 03/31/2019 (Co-PI)
PI: Frederick L. Ruberg, MD
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-02

AN OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF THE ORAL FORMULATION OF MLN9708 ADMINISTERED WEEKLY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY LIGHT-CHAIN (AL) AMYLOIDOSIS WHO REQUIRE FURTHER
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.

A PHASE I/II TRIAL OF POMALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH AL AMYLOIDOSIS
03/01/2012 - 02/28/2019 (PI)
Celgene Corporation

A PHASE II MULTI-CENTER STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION WITH POST TRANSPLANT MAINTENANCE FOR THE TREATMENT OF
01/06/2016 - 01/05/2019 (Co-PI)
PI: Robert W. Simms, MD
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNO
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.

PHASE II TRIAL OF INDUCTION THERAPY WITH BORTEZOMIB AND DEXAMETHASONE FOLLOWED BY HIGH-DOSE MELPHALAN AND STEM CELL TRANSPLANTATION IN PATIENTS WITH AL AMYLOIDOSIS
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.

Showing 10 of 14 results. Show All Results

54767414AMY3001
11/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC

Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center

PRONTO - Protocol NEOD001-201
05/13/2016 - 05/31/2019 (PI)
Prothena Therapeutics Limited

DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC

NEOD001-CL002
09/24/2015 - 09/30/2018 (PI)
Prothena Therapeutics Limited

Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25; 4(1):38. PMID: 30361521.
     
  2. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain (AL) amyloidosis. Blood. 2018 Oct 17.View Related Profiles. PMID: 30333122.
     
  3. Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid. 2018 Jul 21; 1-4.View Related Profiles. PMID: 30032640.
     
  4. Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Jul 21; 1-8.View Related Profiles. PMID: 30032658.
     
  5. Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2018 Sep; 24(9):1823-1827.View Related Profiles. PMID: 29933072.
     
  6. Sarosiek S, Quillen K, Sloan JM, Brauneis D, Sanchorawala V. Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood. 2018 Aug 16; 132(7):755-757.View Related Profiles. PMID: 29903887.
     
  7. White PS, Phull P, Brauneis D, Sloan JM, Quillen K, Sarosiek S, Sanchorawala V. High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplant. 2018 Jun 08.View Related Profiles. PMID: 29884854.
     
  8. Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics. Circ Cardiovasc Imaging. 2018 May; 11(5):e007826.View Related Profiles. PMID: 29752394.
     
  9. Pudusseri A, Smith I, Sarnacki D, Brauneis D, Shelton A, Sanchorawala V, Sloan JM, Sarosiek S, Quillen K. Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfus Apher Sci. 2018 Jun; 57(3):411-415.View Related Profiles. PMID: 29731423.
     
  10. Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection?. Clin Nephrol. 2018 Apr; 89(4):252-259.View Related Profiles. PMID: 29208204.
     
Showing 10 of 151 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 151 publications over 21 distinct years, with a maximum of 15 publications in 2017 and 2018

YearPublications
19941
19982
19991
20014
20021
20035
20046
20055
200611
20076
20082
20097
201012
201112
201210
20135
201410
201510
201611
201715
201815
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research
QoL

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


732 Harrison Ave
Boston MA 02118
Google Map


Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department